Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies
Over the past decade, Medicare Part D expenditures for DMTs targeting immune-mediated neurologic diseases have increased substantially, despite relatively stable claim volumes. These findings show that increases have consistently outpaced inflation rates, adding substantial economic pressure to federally funded neurologic care.
Authors
- Tammy Smith (ORCID: https://orcid.org/0000-0001-9828-2381)
- Heewon Hwang (ORCID: https://orcid.org/0000-0002-0782-6724)
- Erica Marini
- Adam de Havenon (ORCID: https://orcid.org/0000-0001-8178-8597)
- JOHN W. ROSE (ORCID: https://orcid.org/0000-0003-2382-5921)
- Stacey Lynn Clardy (ORCID: https://orcid.org/0000-0001-6600-9428)
- Ka‐Ho Wong (ORCID: https://orcid.org/0000-0001-9597-8105)
- Trieste Francis (ORCID: https://orcid.org/0009-0004-8110-182X)
- Jordan B. King (ORCID: https://orcid.org/0000-0002-6783-7951)
- Abigail Sorenson
- Esther Zeng
- Vivek K. Reddy
- C. Michael Stein
Institutions
- Kaiser Permanente (US)
- University of Utah (US)
- Yale University (US)
- Kaiser Permanente Washington Health Research Institute (US)
- VA Salt Lake City Healthcare System (US)
- Utah Department of Health (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.38277
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alexion Pharmaceuticals
- Novo Nordisk
- EMD Serono